The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Akeso Biopharma; AstraZeneca; GlaxoSmithKline; Mersana; MSD; Novocure; Roche; Sotio
KEYNOTE-C93/GOG-3064/ENGOT-en15: A phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma.
 
Brian M. Slomovitz
Consulting or Advisory Role - Agenus; AstraZeneca; Clovis Oncology; Eisai; EQRx; Genentech; GlaxoSmithKline; GOG Foundation; Incyte; Merck; Myriad Genetics; Nuvation Bio; Onconova Therapeutics; Regeneron
 
David Cibula
No Relationships to Disclose
 
Tayup Simsek
Research Funding - Merck Sharp & Dohme
 
Mansoor Raza Mirza
Leadership - Karyopharm Therapeutics; Sera Prognostics
Stock and Other Ownership Interests - Karyopharm Therapeutics; Sera Prognostics
Honoraria - Allarity Therapeutics; AstraZeneca; Geneos; Genmab/Seattle Genetics; GlaxoSmithKline; Merck; Mersana; Oncology Venture; Roche; Sotio; Takeda; Zai Lab
Consulting or Advisory Role - AstraZeneca; BioCad; Cerulean Pharma; Genmab; GlaxoSmithKline; Karyopharm Therapeutics; Pfizer; Sotio
Research Funding - Apexigen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Pfizer (Inst); Tesaro (Inst); Ultimovacs (Inst)
Patents, Royalties, Other Intellectual Property - AstraZeneca (Inst); GlaxoSmithKline (Inst); Pfizer (Inst); Ultimovacs (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Karyopharm Therapeutics; Pfizer; Roche; SeraCare; Tesaro
Other Relationship - European Network of Gynaecological Oncologic Trials; European Society for Gynaecological Oncology; Gynecological Cancer InterGroup
 
Beata Maćkowiak-Matejczk
Consulting or Advisory Role - Seagan
Research Funding - AstraZeneca; Clovis Oncology; Mersana; MSD; PAREXEL; Quintiles Eastern Holdings; Regeneron; Roche; Seagan; Tesaro
Other Relationship - GSK Commercial; Roche Polska. Sp. z o.o.
 
Emma Hudson
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Merck Sharp & Dohme; Roche
Research Funding - Merck Sharp & Dohme (Inst)
 
Ignacio Romero
Consulting or Advisory Role - AstraZeneca Spain; Clovis Oncology; GlaxoSmithKline; Roche
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; PharmaMar; Roche
Research Funding - GlaxoSmithKline (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche
 
Nicoletta Colombo
Employment - Sarepta Therapeutics (I)
Honoraria - Advaxis; Amgen; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Novartis; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech; Tesaro
Consulting or Advisory Role - Advaxis; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech; Tesaro
 
Jacob Korach
Research Funding - Merck Sharp & Dohme (Inst)
 
Rutie Yin
No Relationships to Disclose
 
Lucy Gilbert
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Merck; Merck/Eisai
Consulting or Advisory Role - GlaxoSmithKline; Merck
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Esperas Pharma (Inst); Immunogen (Inst); IMV (Inst); Karyopharm Therapeutics (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Novocure (Inst); OncoQuest (Inst); Roche (Inst); Tesaro/GSK (Inst)
 
Kosei Hasegawa
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; MSD K.K; Takeda
Consulting or Advisory Role - Kaken Pharmaceutical; MSD K.K
Research Funding - Daiichi Sankyo; Merck; Ono Pharmaceutical
 
Alexandra Tyulyandina
Stock and Other Ownership Interests - Ruspharmtech (I)
Honoraria - AstraZeneca/MedImmune; BioCad; Eisai; MSD Oncology; Roche
Consulting or Advisory Role - AstraZeneca/MedImmune; Eisai; MSD Oncology
Research Funding - AstraZeneca/MedImmune; biocad; MSD Oncology
 
Sally E. Baron-Hay
Consulting or Advisory Role - AstraZeneca; Eisai; GlaxoSmithKline; Merck Sharpe and Doehme; Novartis
 
Lyndsay Willmott
Consulting or Advisory Role - AstraZeneca; Eisai; Genentech; Merck; Seagen
Speakers' Bureau - AstraZeneca; Merck
Research Funding - Merck Sharp & Dohme (Inst)
 
Floor Jenniskens Backes
Consulting or Advisory Role - Abbott Diagnostics (I); Agenus; AstraZeneca; CMR Institute; Eisai; GlaxoSmithKline; Merck
Research Funding - Clovis Oncology (Inst); Eisai (Inst); Immunogen (Inst); Merck (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate (for writing a chapter)
 
Robert J. Orlowski
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck
 
Xuan Zhou
Employment - Merck Sharp & Dohme
 
Vivek Khemka
Employment - Bristol-Myers Squibb; Merck
Stock and Other Ownership Interests - Bristol-Myers-Squibb; Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgene; Merck
 
Sandro Pignata
Honoraria - AstraZeneca; MSD; pfizer; pharmamar; Roche; Tesaro
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Pfizer; PharmaMar; Roche; tesaro
Research Funding - AstraZeneca (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)